We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00229658
First Posted: September 30, 2005
Last Update Posted: March 25, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
AstraZeneca
  Purpose
This is an open label, observational study designed to collect data that characterize the use of SYMLIN following the introduction of the medication into the marketplace. Health care providers and subjects selected for study participation are intended to be representative of those providers prescribing, and subjects receiving, SYMLIN therapy.

Condition Intervention
Type 1 Diabetes Mellitus Type 2 Diabetes Mellitus Drug: pramlintide acetate

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: A Prospective, Open-Label, Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes Following SYMLIN Introduction Into the Marketplace

Resource links provided by NLM:

MedlinePlus related topics: Diabetes Type 1
U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Incidence of Patient-Ascertained Severe Hypoglycemia (PASH) During the Adjustment Period [ Time Frame: 0-3 months ]
    PASH is defined as episodes of hypoglycemia requiring the assistance of another individual (including aid in ingestion of oral carbohydrate); and/or requiring the administration of glucagon injection, intravenous glucose, or other medical intervention. The adjustment period represents the initial 0-3 months of pramlintide treatment

  • Annual Event Rate of Patient-Ascertained Severe Hypoglycemia (PASH) During the Adjustment Period [ Time Frame: 0-3 months ]

    The annual event rate was calculated as the total number of events during the time period divided by the total years of exposure to pramlintide for all patients during the time period. The adjustment period represents the initial 0-3 months of pramlintide treatment.

    PASH is defined as episodes of hypoglycemia requiring the assistance of another individual (including aid in ingestion of oral carbohydrate); and/or requiring the administration of glucagon injection, intravenous glucose, or other medical intervention.



Secondary Outcome Measures:
  • The Incidence of Patient-Ascertained Severe Hypoglycemia (PASH) During the Steady State Period [ Time Frame: >3-6 months ]

    The steady state period represents the >3-6 months of pramlintide treatment following the adjustment period.

    PASH is defined as episodes of hypoglycemia requiring the assistance of another individual (including aid in ingestion of oral carbohydrate); and/or requiring the administration of glucagon injection, intravenous glucose, or other medical intervention.


  • The Annual Event Rate of Patient-Ascertained Severe Hypoglycemia (PASH) During the Steady State Period [ Time Frame: >3-6 months ]

    The annual event rate was calculated as the total number of events during the time period divided by the total years of exposure to pramlintide for all patients during the time period. The steady state period represents the >3-6 months of pramlintide treatment following the adjustment period.

    PASH is defined as episodes of hypoglycemia requiring the assistance of another individual (including aid in ingestion of oral carbohydrate); and/or requiring the administration of glucagon injection, intravenous glucose, or other medical intervention.


  • Incidence of Medically Assisted Severe Hypoglycemia (MASH) During the Adjustment Period [ Time Frame: 0-3 months ]
    MASH is defined as episodes of severe hypoglycemia requiring IM glucagon, IV glucose, hospitalization, paramedic assistance, emergency room visit, and/or is assessed as a serious adverse event (SAE) by the investigator. MASH is a subset of PASH. The adjustment period represents the initial 0-3 months of pramlintide treatment

  • The Annual Event Rate of Medically Assisted Severe Hypoglycemia (MASH) During the Adjustment Period [ Time Frame: 0-3 months ]

    The annual event rate was calculated as the total number of events during the time period divided by the total years of exposure to pramlintide for all patients during the time period. The adjustment period represents the initial 0-3 months of pramlintide treatment.

    MASH is defined as episodes of severe hypoglycemia requiring IM glucagon, IV glucose, hospitalization, paramedic assistance, emergency room visit, and/or is assessed as a serious adverse event (SAE) by the investigator. MASH is a subset of PASH.


  • Incidence of Medically Assisted Severe Hypoglycemia (MASH) During the Steady State Period [ Time Frame: >3-6 months ]

    The steady state period represents the >3-6 months of pramlintide treatment following the adjustment period.

    MASH is defined as episodes of severe hypoglycemia requiring IM glucagon, IV glucose, hospitalization, paramedic assistance, emergency room visit, and/or is assessed as a serious adverse event (SAE) by the investigator. MASH is a subset of PASH.


  • Annual Event Rate of Medically Assisted Severe Hypoglycemia (MASH) During the Steady State Period [ Time Frame: >3-6 months ]

    The annual event rate was calculated as the total number of events during the time period divided by the total years of exposure to pramlintide for all patients during the time period. The steady state period represents the >3-6 months of pramlintide treatment following the adjustment period.

    MASH is defined as episodes of severe hypoglycemia requiring IM glucagon, IV glucose, hospitalization, paramedic assistance, emergency room visit, and/or is assessed as a serious adverse event (SAE) by the investigator. MASH is a subset of PASH.


  • Change in HbA1c From Baseline at Month 3 [ Time Frame: 3 months ]
    Change in HbA1c from baseline at month 3. The HbA1c test measures the percent of glycosylated hemoglobin in the blood.

  • Change in HbA1c From Baseline at Month 6 [ Time Frame: 6 months ]
    Change in HbA1c from baseline at month 6. The HbA1c test measures the percent of glycosylated hemoglobin in the blood.

  • Change in Body Weight From Baseline at Month 3 [ Time Frame: 3 months ]
    Mean change in body weight from baseline at month 3

  • Change in Body Weight From Baseline at Month 6 [ Time Frame: 6 months ]
    Mean change in body weight from baseline at month 6
Enrollment: 1297
Study Start Date: September 2005
Study Completion Date: May 2008
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Type 1
Patients with type 1 diabetes
 Drug: pramlintide acetate
Subcutaneous injection prior to each major meal
Other Name: Symlin
Type 2
Patients with type 2 diabetes
 Drug: pramlintide acetate
Subcutaneous injection prior to each major meal
Other Name: Symlin

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
cross-section of clinical practice settings
Criteria

Inclusion Criteria:

  • The following inclusion criteria are consistent with information in the SYMLIN package insert and apply to insulin using patients with type 2 or type 1 diabetes who:

    • Have failed to achieve the desired or optimal level of glycemic control despite utilizing appropriate, individualized insulin regimens
    • Have A1C <=9.0% within 3 months of study enrollment
    • Are receiving ongoing diabetes care under the guidance of a Health Care Provider (HCP) trained in the use of SYMLIN

Exclusion Criteria:

  • The following exclusion criteria are consistent with the SYMLIN package insert and specifically exclude patients who:

    • Are poorly compliant with their current insulin regimen, as defined by their HCP
    • Are poorly compliant with prescribed blood glucose self monitoring, as defined by their HCP
    • Have experienced recurrent patient-ascertained severe hypoglycemia requiring assistance during the past 6 months
    • Have hypoglycemia unawareness
    • Have a confirmed diagnosis of gastroparesis
    • Require the use of drugs that stimulate gastrointestinal motility
    • Are female and pregnant or lactating and for whom the HCP determines the potential benefit does not justify the potential risk to the fetus or infant
    • Have been treated with SYMLIN within 3 months prior to study start
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00229658


  Show 107 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Vice President, Medical Development, MD Amylin Pharmaceuticals, LLC.
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00229658     History of Changes
Other Study ID Numbers: 137-161
First Submitted: September 28, 2005
First Posted: September 30, 2005
Results First Submitted: May 5, 2009
Results First Posted: June 24, 2009
Last Update Posted: March 25, 2015
Last Verified: February 2015

Keywords provided by AstraZeneca:
diabetes
pramlintide
Symlin
Amylin
phase 4

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
 Pramlintide
Islet Amyloid Polypeptide
Hypoglycemic Agents
Physiological Effects of Drugs
Appetite Depressants
Anti-Obesity Agents
Amylin Receptor Agonists
Molecular Mechanisms of Pharmacological Action